PTC CLINIC
Informace pro odborníky

Přehled publikovaných prací a relevantních studií odborníků Protonového centra k protonové terapii lymfomů:

1. MICHNOVA, Katerina. Protonová radioterapie maligního lymfomu založená na důkazech. Transfuze a hematologie dnes. 2/2024. Protonová radioterapie maligního lymfomu založená na důkazech
2. NTENTAS, George, Katerina DEDECKOVA a Michal ANDRLIK. Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection. Int J Radiat Oncol Biol Phys. 2022, 112(4), 913-925. Proton Therapy in Supradiaphragmatic Lymphoma – Predicting Treatment-Related Mortality to Help Optimize Patient Selection
3. PINNIX, JJ, JR GUNTHER a P FANG. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open. 2020, 3(9), e2013935. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy
4. TRAVIS, LB, DA HILL a GM DORES. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003, 290(4), 465-75. Erratum in: JAMA. 2003 Sep 10;290(10):1318. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease
5. KUMAR, A, C CASULO a RH ADVANI. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021, 39(20), 2257-2265. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma
6. VAN NIMWEGEN, FA, M SCHAAPVELD a CP JANUS. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015, 175(6), 1007-17. Cardiovascular disease after Hodgkin lymphoma treatment 40-year disease risk
7. GALPER, SL, JB YU a PM MAUCH. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011, 117(2), 412-8. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation
8. HOPPE, B. S., C. E. HILL-KAYSER, Y. D. TSENG, et al. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma. Annals of Oncology [online]. 2017, 2017-09-01, 28(9), 2179-2184 [cit. 2018-10-26]. ISSN 0923-7534. Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma
9. LOAP, L, A MIRANDOLA a L DE MARZI. Current Situation of Proton Therapy for Hodgkin Lymphoma: From Expectations to Evidence. Cancers (Basel). 2021, 13(15), 3746. Current Situation of Proton Therapy for Hodgkin Lymphoma From Expectations to Evidence
10. ANDRÉ, MPE, P CARDE a S VIVIANI. Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. Cancer Med. 2020, 9(18), 6565–6575.Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma A pooled analysis of four randomized trials
11. FUCHS, M, H GOERGEN a C KOBE. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol. 2019, 37(31), 2835-2845. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma
12. PEI, F, Y YU a B DONG. Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma. Front. Pharmacol. 2021, 12. Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
13. TSENG, Yolanda D., David J. CUTTER, John P. PLASTARAS, et al. Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. International Journal of Radiation Oncology*Biology*Physics [online]. 2017, 99(4), 825-842 [cit. 2018-10-26]. ISSN 03603016. Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee
14. ANDRÉ, MPE, T GIRINSKI a M FEDERICO. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017, 35(16), 1786-1794. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma Final Results of the Randomized EORTCLYSAFIL H10 Trial
15. HOULIHAN, OA, G NTENTAS a DJ CUTTER. Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma. Clin Transl Oncol. 2022. Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
16. MARKOVA, J., C. KOBE, M. SKOPALOVA, et al. FDG–PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin’s lymphoma has a high negative predictive value. Annals of Oncology [online]. 2009, 2009-7-01, 20(7), 1270-1274 [cit. 2018-10-26]. ISSN 1569-8041. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin’s lymphoma has a high negative predi
17. ALEMAN, BM, AW VAN DEN BELT-DUSEBOUT a ML DE BRUIN. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood [online]. 2007, 109(5), 1878-86 [cit. 2023-09-01]. Late cardiotoxicity after treatment for Hodgkin lymphoma
18. ZENG, Chuan, John P. PLASTARAS, Paul JAMES, Zelig A. TOCHNER, Christine E. HILL-KAYSER, Stephen M. HAHN a Stefan BOTH. Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment. Acta Oncologica [online]. 2016, 2016-06-22, 55(9-10), 1132-1138 [cit. 2018-10-26]. ISSN 0284-186X.Proton pencil beam scanning for mediastinal lymphoma treatment planning and robustness assessment
19. BARON, JA, CM WRIGHT a R MAXWELL. Proton Radiation Therapy After Chemotherapy in the Management of Aggressive Mediastinal Non-Hodgkin Lymphomas: A Particle Therapy Cooperative Group Lymphoma Subcommittee Collaboration. Adv Radiat Oncol. 2022, 8(1), 101090. Proton Radiation Therapy After Chemotherapy in the Management of Aggressive Mediastinal Non-Hodgkin Lymphomas
20. BAUES, C, S MARNITZ a A ENGERT. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation : A PLANNING COMPARISON OF DEEP INSPIRATION BREATH HOLD INTENSITY MODULATION RADIOTHERAPY AND INTENSITY MODULATED PROTON THERAPY. Radiat Oncol. 2018, 13(1), 122. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation
21. RADFORD, J, T ILLIDGE a N COUNSELL. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015, 372(17), 1598-607. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma
22. FRANKLIN, J, A PLUETSCHOW a M PAUS. Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006, 17(12), 1749-60. Second malignancy risk associated with treatment of Hodgkin’s lymphoma meta-analysis of the randomised trials
23. NG, AK, MV BERNARDO a E WELLER. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002, 100(6), 1989-96. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy long-term risks and risk factors
24. KÖNIG, L, P HAERING a C LANG. Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk. Front Oncol. 2020, 10, 989. Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma
25. Ntentas Georgios DPhil, Dedeckova Katerina MD, Andrlik Michal MSc, Aznar Marianne C. PhD, George Ben PhD, Kubes Jirí MD, PhD, C. Darby Sarah PhD,. Cutter David J FRCR, DPhil. Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? Practical Radiation Oncology (2019) 9, 179-187.
26. Shbib Dabaja, B., Hoppe, B., Plastaras, J., Newhauser, W., Rosolova, K., Flamour, S., Mohan, R., Mikhaeel, G., Kirova, Y., Specht, L., Yahalom, J. (2018). Proton therapy for adults with mediastinal lymphomas: the international lymphoma radiation oncology group (ilrog) guidelines. Blood. Retrieved from http://www.bloodjournal.org/content/early/2018/08/14/blood-2018-03-837633.long?sso-checked=true.
27. Ntentas, G., Dědečková K., Andrlik, M., Aznar, M.C., George, B., Darby, S.C., Cutter, D. (2017). Predicted cardiac and second cancer risks in hodgkin lymphoma patients treated with advanced proton beam therapy compared to photon radiation therapy. S181 ASTRO Annual Metting. International Journal of Radiation Oncology, Biology, Physics, 99(2). doi: https://doi.org/10.1016/j.ijrobp.2017.06.454.
28. Yolanda D. Tseng, MD, David J. Cutter, MD, DPhil, FRCR, John P. Plastaras, MD, PhD, Rahul R. Parikh, MD, Oren Cahlon, MD, Michael D. Chuong, MD, Katerina Dedeckova, MD, Mohammad K. Khan, MD, PhD, Shinn-Yn Lin,MD, Lisa A. McGee, MD, Eric Yi-Liang Shen, MD, Stephanie A. Terezakis, MD, Shahed N. Badiyan, MD, Youlia M. Kirova, MD, Richard T. Hoppe,MD, Nancy P. Mendenhall, MD, Mark Pankuch, PhD, Stella Flampouri, PhD, Umberto Ricardi, MD, and Bradford S. Hoppe, MD, MPH. Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee International Journal for Radiation Oncology, Biology, Physics. (2017) Nov 15; 99(4):825-842. doi: 10.1016/j.ijrobp.2017.05.004. Epub 2017 Sep 21.
29. Dedeckova, K., Stokucova J., Mocikova, H., Markova, J., Gaherova, L., Kantorova, I., Ondrova, B., Vondracek, V., Vitek, P., Kubes, J. (2016). Pencil beam scanning proton therapy for lymphoma patients with mediastinal involvement: Prague´s single institution experience. PTCOG Conference. Retrieved from https://www.czech-in.org/cm/PTCOG/CM.NET.WebUI/CM.NET.WEBUI.scpr4/SCPRfunctiondetail.aspx?confID=05000000-0000-0000-0000-000000000066&sesID=05000000-0000-0000-0000-000000004711&absID=07000000-0000-0000-0000-000000036887
30. Dedeckova K., Markova J., Gaherova, L., Kantorova, I., Ondrova, B., Vondracek, V., Vitek, P., Kubes, J. (2016). Proton radiotherapy for mediastinal Hodgkin lymphoma: single institution experience. 10th International Symposium on Hodgkin Lymphoma. Retrieved from https://www.hodgkinsymposium.org/media/469-f203b911.
31. Dedeckova, K., Mocikova, H., Markova, J., Gaherova, L., Koren, J., Backova, B., Vondracek, V., Sindelar, D., Kohlova, T., Ondrova, B., Kantorova, I., Vitek, P., Pytlik, R., Kubes, J. (2015). Pencil Beam Scanning Proton Therapy for Lymphoma Patients with Mediastinal Involvement: A Dosimetric Study and Preliminary Clinical Data. Hematological Oncology, 33, 191. Retrieved from http://www.lymphcon.ch/icml/website/doc/ICML_AbstractBooks_vecchi/13-ICMLJune%2017-202015/13-ICML_AB_Poster.pdf.
32. Kubeš, J., Vítek, P., Dědečková, K., Ondrová, B. (2014). Velmi pozdní následky radioterapie – limitující faktor současných radioterapeutických Technik (Very late side effects of radiotherapy – limiting factor of current radiotherapeutic techniques). Klinicka onkologie Journal, 27(3), 161-165. doi: 14735/amko2014161.
33. Dědečková K, Móciková H, Belada D, Janíková A, Dolečková M, Malinová B, Feltl D, Vošmik M, Svoboda T, Marková J, Trněný M. (2013). The role of radiotherapy in the treatment of malignant lymphomas – recommendations of the Czech Lymphoma Study Group. Klinicka onkologie Journal, 26(2), 99-109. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23718668. PubMed PMID: 23718668.
34. Dědečková, K., Móciková, H., Belada, D., Obořilová-Janíková, A., Dolečková, M., Malinová, B., Feltl, D., Vošmik, M., Svoboda, T., Marková, J., Trněný, M.(2013). Postavení radioterapie v léčbě maligních lymfomů – doporučení Kooperativní lymfomové skupiny (The Position of radiotherapy in the treatment of malignant lymphomas – recommendations of the cooperative lymphoma group). Klinicka onkologie Journal, 26(2), 99-109. doi: 14735/amko201399.
35. Marková J., Kahraman D., Kobe C., Skopalová M., Móciková H., Klásková K., Dědečková, , Eich H.T., Böll B., Dietlein M., Kozák T. (2012). Role of (18F)-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leukemia & Lymphoma, 53(1), 64-70. doi: 10.3109/10428194.2011.603444.
36. Chocenská, E., Móciková, H., Dědečková K. (2010). Průvodce pacienta onkologickou léčbou (Patient’s Guide to Cancer Treatment). Retrieved from https://www.linkos.cz/pacient-a-rodina/pomoc-v-nemoci/kde-hledat-informace/onkologicke-knihy/pruvodce-pacienta-onkologickou-lecbou/.
37. Marková J., Kobe C., Skopalová M., Klásková K., Dědečková, Plütschow A., Eich H.T., Dietlein M., Engert A., Kozák T. (2009). FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin’s lymphoma has a high negative predictive value. Annals of Oncology, (20)7. 1270-4. doi: 10.1093/annonc/mdn768.
38. Marková, J., Kobe C., Skopalová, M., Žikavská, L., Vernerová, Z., Klásková, K., Dědečková, K., Eich, H.T., Dietlein, M., Fuchs, M., Engert, A., Kozák, T. (2009). Early and late response assessment with fdg-pet after beacopp-based chemotherapy in advanced-stage Hodgkin lymphoma patients has a high negative predictive value. Haematologica, 94(2). Retrieved from http://online.haematologica.org/EHA14/browserecord.php?-action=browse&-recid=3189
39. Tseng YD, Hoppe BS, Dedeckova K, Patel CG, Hill-Kayser CE, Miller DM, Maity A, Mendenhall NP, Mailhot Vega RB, Yock TI, Baliga S, Hess CB, Winkfield KM, Mohindra P, Rosen LR, Tsai H, Chang J, Hartsell WF, Plastaras JP. Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relepsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1): 220-230. doi: https://doi.org/10.1016/j.ijrobp.2020.08.055
40. Loap P, Mirandola A, De Marzi L, Dendale R, Iannalfi A, Vitolo V, Barcellini A, Filippi AR, Jereczek-Fossa BA, Kirova Y, Orlandi E. Current Situation of Proton Therapy for Hodgkin Lymphoma: From Expectations to Evidence. Cancers (Basel). 2021 Jul 26;13(15):3746. doi: 10.3390/cancers13153746. PMID: 34359647; PMCID: PMC8345146.https://www.mdpi.com/2072-6694/13/15/3746
41. Loap P, De Marzi L, Mirandola A, Dendale R, Iannalfi A, Vitolo V, Barcellini A, Filippi AR, Jereczek-Fossa BA, Kirova Y, Orlandi E. Development and Implementation of Proton Therapy for Hodgkin Lymphoma: Challenges and Perspectives. Cancers (Basel). 2021 Jul 26;13(15):3744. doi: 10.3390/cancers13153744. PMID: 34359644; PMCID: PMC8345082. https://www.mdpi.com/2072-6694/13/15/3744
42. Tringale KR, Modlin LA, Sine K, Forlenza CJ, Cahlon O, Wolden SL. Vital organ sparing with proton therapy for pediatric Hodgkin lymphoma: Toxicity and outcomes in 50 patients. Radiother Oncol. 2022 Mar;168:46-52. doi: 10.1016/j.radonc.2022.01.016. Epub 2022 Jan 29. PMID: 35101461; PMCID: PMC9446376 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446376/
43. Baues C, Marnitz S, Engert A, Baus W, Jablonska K, Fogliata A, Vásquez-Torres A, Scorsetti M, Cozzi L. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation : A PLANNING COMPARISON OF DEEP INSPIRATION BREATH HOLD INTENSITY MODULATION RADIOTHERAPY AND INTENSITY MODULATED PROTON THERAPY. Radiat Oncol. 2018 Jul 3;13(1):122. doi: 10.1186/s13014-018-1066-2. PMID: 29970105; PMCID: PMC6029162. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029162/
44. Patel CG, Peterson J, Aznar M, Tseng YD, Lester S, Pafundi D, Flampouri S, Mohindra P, Parikh RR, Mailhot Vega R, Konig L, Plastaras JP, Bates JE, Loap P, Kirova YM, Orlandi E, Lütgendorf-Caucig C, Ntentas G, Hoppe B. Systematic review for deep inspiration breath hold in proton therapy for mediastinal lymphoma: A PTCOG Lymphoma Subcommittee report and recommendations. Radiother Oncol. 2022 Dec;177:21-32. doi: 10.1016/j.radonc.2022.10.003. Epub 2022 Oct 14. PMID: 36252635.
45. Tseng YD, Pankuch M, Mohindra P, McGee L, Rossi C, Flampouri S, Hajj C, Molitoris JK, Chang JH, Tsai H, Stevens C, Rosen L, Vargas C, Hartsell W. Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry: Concordance With the ILROG Guidelines. Am J Clin Oncol. 2021 Jun 1;44(6):269-274. doi: 10.1097/COC.0000000000000819. PMID: 33852456.
46. Ntentas G, Dedeckova K, Andrlik M, Aznar MC, Shakir R, Ramroth J, Begum R, Kubeš J, Darby SC, Mikhaeel NG, Cutter DJ. Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection. Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):913-925. doi: 10.1016/j.ijrobp.2021.10.151. Epub 2021 Nov 9. PMID: 34762970; PMCID: PMC8865523. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865523/
47. Loap P, Orlandi E, De Marzi L, Vitolo V, Barcellini A, Iannalfi A, Dendale R, Kirova Y, Mirandola A. Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy. Acta Oncol. 2022 Aug;61(8):979-986. doi: 10.1080/0284186X.2022.2084639. Epub 2022 Jun 6. PMID: 35668710. https://www.tandfonline.com/doi/full/10.1080/0284186X.2022.2084639
48. Buglione M, Guerini AE, Filippi AR, Spiazzi L, Pasinetti N, Magli A, Toraci C, Borghetti P, Triggiani L, Alghisi A, Costantino G, Bertagna F, Giaj Levra N, Pegurri L, Magrini SM. A Systematic Review on Intensity Modulated Radiation Therapy for Mediastinal Hodgkin’s Lymphoma. Crit Rev Oncol Hematol. 2021 Nov;167:103437. doi: 10.1016/j.critrevonc.2021.103437. Epub 2021 Aug 3. PMID: 34358649.
49. Dionisi F, Scartoni D, Rombi B, Vennarini S, Righetto R, Farace P, Lorentini S, Schwarz M, Di Murro L, Demofonti C, D’Angelillo RM, Petrongari MG, Sanguineti G, Amichetti M. Consolidative active scanning proton therapy for mediastinal lymphoma: selection criteria, treatment implementation and clinical feasibility. Strahlenther Onkol. 2022 Jun;198(6):558-565. doi: 10.1007/s00066-022-01918-1. Epub 2022 Apr 8. PMID: 35394144.
50. O’steen L, Bellardini J, Cury J, Jones L, Seeram VK, Mendenhall NP, Hoppe BS. Pulmonary Function after Proton Therapy for Hodgkin Lymphoma. Int J Part Ther. 2019 Winter;5(3):1-4. doi: 10.14338/IJPT-18-00040.1. Epub 2019 Mar 21. PMID: 31788502; PMCID: PMC6874186.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874186/
51. Rosenbrock J, Baues C, Vasquez-Torres A, Clivio A, Fogliata A, Borchmann P, Marnitz S, Cozzi L. Volumetric modulated arc therapy versus intensity-modulated proton therapy in the irradiation of infra diaphragmatic Hodgkin Lymphoma in female patients. Acta Oncol. 2022 Jan;61(1):81-88. doi: 10.1080/0284186X.2021.1986230. Epub 2021 Oct 1. PMID: 34596491.https://www.tandfonline.com/doi/full/10.1080/0284186X.2021.1986230
52. Bates JE, Terezakis S, Morris CG, Rao AD, Sehgal S, Kumar R, Mailhot Vega RB, Mendenhall NP, Hoppe BS. Comparative Effectiveness of Proton Therapy versus Photon Radiotherapy in Adolescents and Young Adults for Classical Hodgkin Lymphoma. Int J Part Ther. 2021 Jul 8;8(3):21-27. doi: 10.14338/IJPT-21-00011.1. PMID: 35127972; PMCID: PMC8768899. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768899/

Mapa komplexních onkologických a hematoonkologických center

https://www.linkos.cz/pacient-a-rodina/lecba/kde-se-lecit/onkologicka-pracoviste/#search=1

Tuzemské zdroje informací

www.hodgkin.cz  odborná veřejnost i pacienti, komplexní informace o Hodgkinově lymfomu pro lékaře i pacienty, brožura a poradna pro pacienty.

www.lymphoma.cz odborná veřejnost i pacienti, komplexní informace týkající se problematiky Hodgkinova I non-Hodgkinova lymfomu, k dispozici aktuální doporučení pro diagnostiku a léčbu lymfomů včetně RT.

www.lymfomhelp.cz pacienti, komplexní informace a pomoc pro pacienty před, v léčbě či po léčbě lymfomu.

www.linkos.cz odborná veřejnost i pacienti, stránky České onkologické společnosti.

www.srobf.cz  odborná veřejnost, stránky Společnosti radiační onkologie, biologie a fyziky.

https://www.amelie-zs.cz/ Projekt psychosociální pomoci, pro pacienty s nádorovým onemocněním.

Zahraniční zdroje informací

www.nccn.org odborná veřejnost i pacienti, doporučení (guidelines) pro jednotlivé typy zhoubných nádorů včetně doporučených technik ozáření.

https://www.ptcog.ch/index.php/other-ptcog-sub-committees?id=53  odborná veřejnost, informace o publikacích týkající se protonové RT lymfomů.

www.ilrog.com odborná veřejnost, informace o postavení a provedení radioterapie u lymfomů.

www.ihaddcancer.com , projekt svépomoci a sdílení zkušeností pacientů, kteří se léčili nebo léčí s rakovinou.

Videa k protonové RT lymfomů (anglicky):

https://www.youtube.com/watch?v=prh-5CQ3nsY, dr. Gomez, Proton Therapy Treatment for Lymphoma, MD Anderson Proton Therapy Center.

https://www.youtube.com/watch?v=NNLoQSaAuzA , dr.Hoppe, Proton Therapy for Lymphoma, University of Florida Proton Therapy Institute.

https://www.youtube.com/watch?v=VlKlPuKrSSw, dr.Dabaja, Proton and photon therapy in managing hematological malignancies, MD Anderson Cancer Center, Houston, TX.